Startups

Nalu Medical

Carlsbad, California, United States

Medical-device company founded by Keegan Harper, developing miniature externally powered neurostimulation for peripheral-nerve/spinal pain. Boston Scientific completed its acquisition January 27, 2026. Historical Carlsbad headquarters; post-acquisition executive roles require confirmation.

Founded 2014

Team

Earl R. FenderHistorical President and CEO (appointed April 2020)

Keegan HarperCo-founder

Tom WestHistorical President and CEO (2024)

Investments

$85M2024-03-05	Gilde Healthcare, Novo Holdings, Longitude, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida Investments, Aperture Venture Partners, B Capital
$104MUnknown date	Gilde Healthcare

team@apexlogos.ai15 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: NaluMedical. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/1 # Nalu Medical Accessed: 2026-10-06. Research report for human review; no database changes made. Direct image URLs are extracted source assets, not invented filenames. Funding ledger is verified events found, not a complete lifetime total. ## Identity and pasted claims [Nalu Medical, Inc.](https://www.nalumed.com/) is a real acquired medical-device company, founded2014, historically based Carlsbad, California. Its miniaturized, externally powered neurostimulation system treats chronic peripheral-nerve/spinal pain; it is not a brain communication BCI. Founder **Keegan Harper** is explicitly named by the [April23 2020 company CEO announcement](https://nalumed.com/nalu-medical-inc-appoints-new-chief-executive-officer-earl-r-fender-joins-as-president-ceo/). Pasted ACQUIRED passes with an important exact chronology: agreement October17 2025, **completion January27 2026**, disclosed in [Boston Scientific’s annual report](https://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR-V3/2025-annual-report.pdf). Old nalumed.com pages now redirect on direct HTML fetch to a Boston Scientific-branded [Nalu IFU site](https://www.nalumed.com/us/en/IFUs.html), whereas web search still exposes historical content. Tom West was CEO in financing announcements; do not assume that historical title remains a current independent-company position following integration. Carlsbad is historical Nalu HQ, not a claim that Boston parent moved there. Pasted USD446M total is not substantiated by a reconciled equity ledger. Acquisition value is separate from venture financing and must not be added to the total. ## Logo / founder / public team Current Nalu logo: https://www.nalumed.com/content/dam/bsc/us/nmd/pain/nalu/site/Logo.svg — actual image source from current Boston-branded Nalu site. | Person | Role / currency | Profile and evidence | Direct pfp URL | |---|---|---|---| | Keegan Harper | Co-founder2014, former CEO; board chair last confirmed2020 | [Official founder/transition announcement](https://nalumed.com/nalu-medical-inc-appoints-new-chief-executive-officer-earl-r-fender-joins-as-president-ceo/) | Unavailable: current site redirects historical team pages; no safely attributable portrait URL captured. | | Earl R. Fender | Historical president/CEO appointed April2020 | [Official transition](https://nalumed.com/nalu-medical-inc-appoints-new-chief-executive-officer-earl-r-fender-joins-as-president-ceo/) | Unavailable: article has an image link but attributable standalone portrait requires confirmation. | | Tom West | Historical president/CEO in2024; current post-acquisition role unverified | [2024 company financing](https://nalumed.com/nalu-medical-inc-closes-85-million-series-e-round/) | Unavailable: old team page redirected to current IFUs on direct fetch. | | Jim Cassidy | Current acquiring parent SVP/president Neuromodulation; not Nalu CEO | [2026 Boston business announcement](https://news.bostonscientific.com/nalu-medical-acquisition-chronic-peripheral-nerve-pain); [portrait source](https://news.bostonscientific.com/four-things-to-know-about-Relievant-Medsystems-acquisition) | https://news.bostonscientific.com/image/Cassidy+Jim+2+3-10-20+inset+2.jpg | ## Financing and acquisition ledger | Announced | Amount | Type | Lead / participants | Evidence | |---|---|---|---|---| | 2022 | USD104M | Equity financing | Gilde Healthcare confirmed co-lead, other named investors/date not established from reviewed primary source; do not import investor guesses | [Company-authored announcement](https://www.linkedin.com/posts/nalu-medical-inc_nalu-engineeredtobemore-npower-activity-6900204274211446785-Ju-U); [investor retrospective](https://gildehealthcare.com/news/all/boston-scientific-to-acquire-nalu-medical/) | | 2024-01-03 (closed lateDec2023) | USD65M | Initial SeriesE close | Novo Holdings lead; existing Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida Investments, Aperture Venture Partners | [Company release](https://nalumed.com/nalu-medical-inc-announces-65-million-equity-financing/) | | 2024-03-05 | USD20M additional; total SeriesE USD85M | Extension / final close of SAME round | B Capital additional20M; initial65M retained, **not85M extra** | [Company final-close release](https://nalumed.com/nalu-medical-inc-closes-85-million-series-e-round/) | | 2025-10-17 agreement; 2026-01-27 completed | USD533M for remaining≈91%; USD517M cash net of acquired cash | Acquisition, not financing | Acquirer Boston Scientific; previous≈9% already owned | [Agreement](https://news.bostonscientific.com/2025-10-17-Boston-Scientific-Announces-Agreement-to-Acquire-Nalu-Medical%2C-Inc); [annual-report close disclosure](https://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR-V3/2025-annual-report.pdf) | No Nalu IPO established; stock of acquiring parent is BSX. No grants/debt established from this partial ledger. Do not sum USD65M and USD85M into150M: the85M already includes65M. Round data are not a verified446M lifetime total. ## Review / import decision Enrich existing `NaluMedical`: mark acquired by `BostonScientific` with completed date and historical standalone team dates. Existing record’s65M financing should be represented as the firstclose of85M SeriesE, not duplicated. Preserve Nalu as acquired operating brand/legal subsidiary unless dissolution is proven; ACQUIRED does not equal closed. Current team/importable executive role and historical portraits remain review gaps.